⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Altrovia and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Altrovia
↗Athens, Greece
Altrovia is an AI-enabled protocol intelligence platform designed to assist clinical development teams at CROs and pharmaceutical companies. The platform streamlines trial design by benchmarking against historical data and validating protocols against regulatory precedent to prevent costly amendments and accelerate submission approvals.
The company operates as an AI-native startup, focusing on transforming the clinical trial lifecycle through simulation, recruitment optimization, and decentralized monitoring. It is currently in private deployment with organizations across enterprise pharma, emerging biotech, CROs, and the public sector.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:-
Industry:Digital Health
Sub-Industry:Clinical Trial Software / AI
SIZE & FINANCIALS
Employees:1-50
Founded:2025
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:OpenAI (via Greek Startup Accelerator), Endeavor Greece
PIPELINE
Stage:Discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Pfizer (Start4Health 2025 cohort), OpenAI (Greek Startup Accelerator), BiHELab (Ionian University)
COMPETITION
Position:Emerging
Competitors:Veeva Systems, Medidata Solutions, Unlearn.ai
LEADERSHIP
Key Executives:
Christos Zoukos - Co-founder
Georgia Lytra - Co-founder
LINKS
Website:altrovia.ai
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Altrovia. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.